CINECA IRIS Institutional Research Information System

VIVALDI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.241
AS - Asia 4.065
EU - Europa 2.849
SA - Sud America 886
AF - Africa 377
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.436
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.070
SG - Singapore 1.512
CN - Cina 1.034
IT - Italia 852
BR - Brasile 749
HK - Hong Kong 695
SE - Svezia 528
DE - Germania 343
VN - Vietnam 290
GB - Regno Unito 263
CI - Costa d'Avorio 221
BG - Bulgaria 180
RU - Federazione Russa 154
AT - Austria 115
CA - Canada 103
FI - Finlandia 103
FR - Francia 100
IN - India 86
TR - Turchia 82
KR - Corea 69
SN - Senegal 58
AR - Argentina 55
JP - Giappone 52
BD - Bangladesh 51
PL - Polonia 43
NL - Olanda 39
IQ - Iraq 35
MX - Messico 33
NG - Nigeria 30
ID - Indonesia 29
ES - Italia 28
EC - Ecuador 24
UA - Ucraina 21
PK - Pakistan 20
VE - Venezuela 19
ZA - Sudafrica 19
MA - Marocco 18
SA - Arabia Saudita 16
LT - Lituania 15
UZ - Uzbekistan 15
AU - Australia 12
IR - Iran 9
RO - Romania 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
CZ - Repubblica Ceca 8
KE - Kenya 8
PA - Panama 8
PE - Perù 8
BE - Belgio 7
CO - Colombia 7
EG - Egitto 7
PY - Paraguay 7
CH - Svizzera 6
IE - Irlanda 6
IL - Israele 6
JO - Giordania 6
MY - Malesia 6
UY - Uruguay 6
CR - Costa Rica 5
HN - Honduras 5
LB - Libano 5
TN - Tunisia 5
TW - Taiwan 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
NZ - Nuova Zelanda 4
PH - Filippine 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
EE - Estonia 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
NP - Nepal 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BJ - Benin 2
BY - Bielorussia 2
ET - Etiopia 2
GD - Grenada 2
GR - Grecia 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CG - Congo 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
FJ - Figi 1
Totale 15.420
Salva come PNG Salva come JPEG
Città #
Ashburn 1.004
Singapore 814
Hong Kong 688
Santa Clara 618
Woodbridge 520
Fairfield 450
Chandler 448
Dallas 446
Houston 356
Ann Arbor 336
Shanghai 298
Abidjan 221
New York 216
Beijing 196
Seattle 181
Wilmington 181
Sofia 179
Los Angeles 172
Boardman 167
Cambridge 165
Milan 121
Princeton 117
London 113
Munich 109
Florence 103
Lawrence 103
Hefei 100
Vienna 90
Pisa 86
Ho Chi Minh City 72
Medford 71
Buffalo 64
Seoul 59
Dakar 58
Istanbul 58
Ottawa 57
Frankfurt am Main 56
Serra 50
São Paulo 50
Redondo Beach 49
Hanoi 48
San Diego 48
Düsseldorf 38
Tokyo 38
Turku 38
Warsaw 35
Des Moines 33
Nuremberg 33
Fuzhou 31
Council Bluffs 30
Lancaster 30
Lagos 28
Rome 28
Bremen 27
Ogden 27
Dearborn 26
Kent 26
Nanjing 26
Helsinki 24
Denver 23
Cascina 22
Baghdad 20
Phoenix 20
Hyderabad 19
Curitiba 18
Poplar 17
Stockholm 17
Dong Ket 16
Hebei 16
Quanzhou 16
Chicago 15
Boston 14
Da Nang 14
Mexico City 14
Montreal 14
Norwalk 14
Rio de Janeiro 14
Seacroft 14
Toronto 14
Belo Horizonte 13
Lappeenranta 13
Tashkent 13
Changsha 12
Chennai 12
Guangzhou 12
Orem 12
Vicopisano 12
Brasília 11
Haiphong 11
Lucca 11
Manchester 11
Porto Alegre 11
Quito 11
Shenyang 11
Boulder 10
Lauterbourg 10
Redwood City 10
The Dalles 10
Bologna 9
Casablanca 9
Totale 10.421
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 309
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 208
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 181
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 176
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 171
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 170
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration 169
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 167
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 164
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 162
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients 161
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 160
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. 160
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 158
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 156
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 152
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 149
Tumor regression grade (TRG) evaluation of 29 borderline/locally advanced pancreatic cancers (LAPCs) after neoadjuvant chemotherapy (NACT) using different pathological scores: a clinical and prognostic correlation 148
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 148
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 146
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 143
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 142
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 141
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 141
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 141
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 141
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 140
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 138
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 137
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 137
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma 136
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 135
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 134
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 130
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. 128
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 127
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 127
Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection 127
Neuroendocrine Liver Metastases 126
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 126
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. 125
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer 125
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 125
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology 125
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 125
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 124
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation 124
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 123
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis 123
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 121
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. 120
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 118
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 118
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 118
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? 117
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 116
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 115
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 115
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions 113
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. 112
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications 112
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 111
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer 111
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 109
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 109
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: Is hepatic arterial infusion chemotherapy the best option? 107
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 107
Cholangiocarcinoma: new perspectives for new horizons 106
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 105
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 105
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 103
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 103
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 100
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 99
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 99
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 99
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 98
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 98
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 98
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 98
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 97
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 96
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer 96
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 95
Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study 94
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres 94
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 93
Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study) 93
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 91
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 91
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 90
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 90
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 89
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 89
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” 89
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 89
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 87
Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors 87
Bone metastases in biliary cancers: A multicenter retrospective survey 86
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 85
Totale 12.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021395 0 0 0 0 0 106 19 39 55 62 30 84
2021/20221.030 14 20 17 27 171 217 30 35 67 81 90 261
2022/20231.863 186 280 154 93 177 206 15 128 450 7 141 26
2023/20241.209 73 96 144 54 161 171 154 47 37 41 90 141
2024/20254.887 28 199 90 236 443 679 371 199 502 553 622 965
2025/20263.671 503 734 632 685 745 372 0 0 0 0 0 0
Totale 15.786